Sep 10, 2007 by Brian LawlerGet a Glimpse of Amgen's FutureDocuments released ahead of an FDA meeting foretell a tougher future for Amgen's top drugs.
Sep 6, 2007 by Brian LawlerFoolish Fantasy Football: GlaxoSmithKline on DefenseGet defensive with GlaxoSmithKline.
Sep 6, 2007 by Brian LawlerFoolish Fantasy Football: InterMune on Special TeamsKick off your portfolio with shares of InterMune.
Sep 6, 2007 by Brian LawlerFoolish Fantasy Football: Gilead Sciences on OffenseGilead packs enough offensive muscle to score in anyone's portfolio.
Sep 6, 2007 by Brian LawlerEncysive, Please StopIts failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant.
Sep 6, 2007 by Brian LawlerAmgen's Congressional HelpersLawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson.
Sep 6, 2007 by Brian LawlerNeurogesX Feels No PainInvestors reward the drugmaker for positive study results.
Sep 5, 2007 by Brian LawlerWhat Is PDL Worth?The drugmaker has more value than the market is giving it credit for.
Sep 5, 2007 by Brian LawlerExelixis Shows Its CardsA small study shows its cancer treatment is comparable to others in terms of usefulness. Safety data is unknown.
Sep 5, 2007 by Brian LawlerNot Your Typical Product RecallShire and Noven will fix an annoying foible of their ADHD patch.
Sep 5, 2007 by Brian LawlerInterMune and the Relativity of TimeThe drugmaker gets a step closer to starting a clinical trial for a hepatitis C drug.
Aug 31, 2007 by Brian LawlerQLT Gets ReformulatedEU approval opens new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
Aug 31, 2007 by Brian LawlerTercica Triumphs With the FDASwiping patients from competitor is a key part of the plan to make the hormone disorder treatment a success.
Aug 31, 2007 by Brian Lawler4 Biotech Bets Under $10Speculative? Sure. But they all have intriguing compounds in development.
Aug 31, 2007 by Brian LawlerNovartis on the Biosimilar AttackThe EU market welcomes the drugmaker's copy of a treatment for anemia.
Aug 30, 2007 by Brian LawlerHuman Genome Steps ForwardA key study of its lead drug proceeds faster than expected.
Aug 29, 2007 by Brian LawlerPDL Lands in a HazardThe biopharma announces a dramatic shift following the failure of its lead drug.
